S&P/ASX 200 Index (ASX: XJO) shares are in the red on Thursday, down 0.15% to 8,709.4 points.
Meanwhile, on The Bull, two experts share their insights on three ASX shares.
Let's review.
Image source: Getty Images
Bannerman Energy Ltd (ASX: BMN)
The Bannerman Energy share price is $3.22, down 0.9% today and down 2.4% over 12 months.
Michael Gable from Fairmont Equities has a buy rating on this ASX energy share.
Gable said:
This uranium development company's flagship Etango project is based in Namibia. We believe the uranium sector presents a bright outlook as we expect demand to outpace supply for the next several years.
Despite BMN de-risking its main resource by announcing a joint venture with the China National Nuclear Corporation, the share price has retreated along with many other stocks in the market.
In our view, this presents a buying opportunity as BMN should be leveraged to any upside in the uranium price.
Saluda Medical Inc (ASX: SLD)
The Saluda Medical share price is steady at 48 cents on Thursday, and down 62% over 12 months.
Stuart Bromley from Medallion Financial Group has a hold rating on this ASX healthcare share.
Bromley said:
SLD is a commercial stage medical device company targeting the global chronic pain market with its Evoke spinal cord stimulation platform.
While commercial execution and adoption remain key milestones to monitor, we continue to believe the company's differentiated technology and growing clinical evidence base support a favourable long term outlook.
Global revenue grew by 34 per cent in the third quarter of fiscal year 2026 when compared to the prior corresponding period.
The company expects full year revenue growth of 24 per cent on the prior corresponding period.
Bapcor Ltd (ASX: BAP)
The Bapcor share price is 42 cents, down 2.3% today and down 89% over 12 months.
Bromley has a sell rating on this ASX consumer discretionary share.
He explains:
Bapcor is an aftermarket automotive parts provider in Australia and New Zealand. It operates the Autobarn, Burson and Autopro brands.
While Bapcor remains a leading participant in its sector, the company continues to face operational challenges, margin pressure and an increasingly difficult consumer environment.
We believe management still has significant work ahead to restore earnings momentum and investor confidence.
Given the availability of alternative opportunities with stronger earnings visibility and growth prospects, we believe capital can be deployed more effectively elsewhere at this time.
The stock has fallen from $5.14 on July 14, 2025 to trade at 40.7 cents on June 25, 2026.
